Companies / MEM

MEMPHASYS LIMITED.

ASX:MEMPharmaceuticals, Biotechnology & Life Sciences
3.09B shares on issueASX (delayed) · as of 28 July 2026$0.008price · delayed$21.6Mmarket cap · indicative
F
Dilution grade

Runway under 2 quarters; share count grew 123% in 24 months; 8 cash raises in 24 months

Cash runway0.6 quarters of funding
Share-count growth (24m)123.3%
Raise cadence (24m)8 cash raises
Options & rights overhang29.4% of shares
In-the-money supply1.8% of shares
Pending proposed issuesopen proposed issue (Appendix 3B)

MEMPHASYS LIMITED.'s ordinary share count grew 123.3% between June 2024 and June 2026, to 3.09B shares. The company raised capital eight times in that period for total disclosed proceeds of A$10.3M, most recently a A$1.2M placement in June 2026. Options and rights on issue could convert into 907M new shares, equal to 29.4% of the current share count, of which 2% are in the money at the current share price; the nearest expiry falls in August 2026. At the June 2026 quarter the company reported A$768K in available cash, about 0.6 quarters of funding at its recent spending rate. One proposed securities issue (Appendix 3B) is pending, with an expected issue date in August 2026.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
29.4%
Max option dilution
1.8%
ITM option dilution
3
Raises · last 12 months
0.6 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 3.09B per ASX (delayed) (28 July 2026).
2.04B2.43B2.81BDec 24Sept 25July 26Cash raise · 12 June 2026Cash raise · 3 Feb 2026Cash raise · 22 Sept 2025Cash raise · 9 Apr 2025Cash raise · 9 Apr 2025Cash raise · 20 Dec 2024

Cash runway

0.6 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$768k available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
26 June 20262A · quoted issueMEM : ORDINARY FULLY PAID3.09BAppendix 2A
20 Feb 20263H · cancellationMEM : ORDINARY FULLY PAID2.85BAppendix 3H
16 Feb 20262A · quoted issueMEM : ORDINARY FULLY PAID2.85BAppendix 2A
23 Jan 20263H · cancellationMEM : ORDINARY FULLY PAID2.69BAppendix 3H
15 Jan 20263G · unquotedMEM : ORDINARY FULLY PAID2.69BAppendix 3G
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

8 cash raises in the last 24 months · 3 in the last 12 months

$1.2M
Placement
12 June 2026 COMPLETE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

1 proposed issue pending — Appendix 3B lodged, securities not yet issued. New shares from these issues are not in the counts above until quoted.
Paid plan
Pending issue detail
Size, price, fees, broker and placement-capacity usage for each pending issue.
Join the waitlist

Options & convertible securities

29.4%
Total overhang · of current shares
1.8%
In the money · at current price
906.6M
Potential new shares
Aug 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
19 Dec 2025Dr Lindley EdwardsOther5.8M——3Y notice
19 Dec 2025Marjan MikelOther6.7M27.0M$20k3Y notice
20 Oct 2025Mathew WatkinsOther———3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

22 July 2026Proposed issue of securities - MEM
22 July 2026Notice of General Meeting/Proxy Form
15 July 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
15 July 2026Becoming a substantial holder
6 July 2026Memphasys Enters into Consulting Agreement with Director
30 June 2026$PExclusive Thailand Commercialisation Agreement Secured
26 June 2026Section 708A Cleansing Statement
26 June 2026Application for quotation of securities - MEM
24 June 2026$PUK Market Entry & Acceleration of Commercial Expansion
24 June 2026Investor Presentation - June 2026
23 June 2026Memphasys Investor Webinar
17 June 2026Proposed issue of securities - MEM
17 June 2026$PSuccessful $1.2M Placement and Convertible Note Extended
16 June 2026$PTrading Halt
15 June 2026$PPause in Trading
15 June 2026$PMemphasys Executes Supply Agreement with Monash IVF Group
31 May 2026$PSouth-East Asian Commercialization Agreement Secured
26 May 2026$PITL Orders 1000 Felix Cartridges Across MENA Markets
25 May 2026Initial Director's Interest Notice
25 May 2026Final Director's Interest Notice

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.